about
Inflammatory pathways of importance for management of inflammatory bowel diseaseAdapter protein Shc regulates Janus kinase 3 phosphorylationAn N-ethyl-N-nitrosourea (ENU)-induced dominant negative mutation in the JAK3 kinase protects against cerebral malariaIdentification of molecular switch regulating interactions of Janus kinase 3 with cytoskeletal proteins.Role of Janus kinase 3 in mucosal differentiation and predisposition to colitisFunctional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres.Janus kinase 3: the controller and the controlledA GEF-to-phospholipase molecular switch caused by phosphatidic acid, Rac and JAK tyrosine kinase that explains leukocyte cell migrationNormal and malignant megakaryopoiesis.The use of structural biology in Janus kinase targeted drug discovery.JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.Emerging targeted therapies in myelofibrosis.Potential targets for colorectal cancer prevention.The role of hypoxia in inflammatory disease (review)T-cell chronic lymphocytic leukemia or small-cell variant of T-cell prolymphocytic leukemia: a historical perspective and search for consensus.Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cellsDevelopment of Selective Covalent Janus Kinase 3 Inhibitors.Downregulation of chloride channel ClC-2 by Janus kinase 3.JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma.Janus kinase 3 regulates adherens junctions and epithelial mesenchymal transition through β-catenin.T Helper 2 Cytokine Signaling in Bone Marrow-Derived Fibroblasts: A Target for Renal Fibrosis.A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy.Angiostatic properties of sulindac and celecoxib in the experimentally induced inflammatory colorectal cancer.Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes.Regulation of Voltage-Gated K+ Channel Kv1.5 by the Janus Kinase JAK3.Upregulation of excitatory amino acid transporters by coexpression of Janus kinase 3.
P2860
Q27005445-8D8BC962-7BAE-4E7D-B205-E67A414AA3B8Q33718415-E01907C2-2D19-49B5-B258-3542C06B015AQ34170436-E9C31D65-A473-4963-A83E-010F7C4AF88AQ34301976-F81C806A-8B44-4C62-9FCD-185FEA3A8AECQ34371948-1C866D98-3EAB-4520-8CDA-BBAD5B43EAC0Q35072638-0E195FBE-A705-4BCB-BC6C-F0301D9D154EQ35228409-7224812E-B102-4646-A269-C13EC45E1D24Q35770946-C6948E50-A0D6-4AC2-A00B-F3DC4D5F7DBAQ36815727-F8748F8B-4575-4419-A1B8-AF3F21E7616CQ36909019-93DF63D8-7692-4F09-9FA1-8EB0849CD2FFQ37206115-FD00CF4B-70EF-47B9-8AAE-510D49EAC3AAQ37808703-2DC96C1C-BD29-41C8-B94C-5C4382109D35Q38025160-3B598AB7-04BC-4CC8-B026-250D745370B8Q38131401-69125E62-8159-4440-8D46-D7E29975E3A7Q38334119-0E98A08B-910E-43FE-A47F-516326E88A41Q38407679-F2BE0F4B-2325-46D3-BF65-E71E4B775420Q38741546-79834E80-547D-4B96-93B4-44D7E9E514D7Q38763094-9C65D2F1-7E5A-4BDD-AD59-B57FADB2B04BQ39016726-85706CED-B162-4911-BD3E-6540D05B6A49Q39149556-09F1E450-1392-427D-9788-844FEDECCB77Q39494833-F8135664-EB75-447F-89B0-006DE2BD36FDQ39717742-D5F3580D-FAA5-440B-B39A-9372C505CA59Q40688204-07882487-1F54-40AC-B5DE-5D823F285E92Q42269413-EDC18A9D-CCE5-4907-A8EF-8EB19CF56FC4Q42722727-10D0D63E-06E1-4107-AA04-494C9817AAB4Q43135354-1F49B2C8-9A7D-46E1-9537-529A0F127C40Q43601028-D7F03445-E3A1-44BD-9FBA-FAF55CDEC086Q45332740-DA9E56C8-FBC3-4AE8-8211-67BA399E6BD4Q48575707-83CADBFE-8273-43D7-A7BA-9FB8FB587314Q48600356-5048FE56-D09F-4505-9133-E107F81F8B6A
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
JAK3: a two-faced player in hematological disorders
@en
JAK3: a two-faced player in hematological disorders.
@nl
type
label
JAK3: a two-faced player in hematological disorders
@en
JAK3: a two-faced player in hematological disorders.
@nl
prefLabel
JAK3: a two-faced player in hematological disorders
@en
JAK3: a two-faced player in hematological disorders.
@nl
P2860
P1476
JAK3: a two-faced player in hematological disorders
@en
P2093
Melanie G Cornejo
Titus J Boggon
P2860
P304
P356
10.1016/J.BIOCEL.2009.09.004
P577
2009-09-09T00:00:00Z